SciELO - Scientific Electronic Library Online

vol.66 issue6Optic nerve glioma: neuro-ophthalmologic findings in a patient with neurofibromatosis type I author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links


Revista Brasileira de Oftalmologia

Print version ISSN 0034-7280On-line version ISSN 1982-8551


MACEDO, Erick Marcet Santiago de; CARNEIRO, Rachel Camargo  and  MATAYOSHI, Suzana. New aproach to periocular basal cell carcinoma treatment: imiquimod. Rev. bras.oftalmol. [online]. 2007, vol.66, n.6, pp.411-417. ISSN 0034-7280.

The basal cell carcinoma is the most common neoplasia of the periocular region, being responsible for 90% of the eyelid malignancies. There has been a significant rate of increase of the neoplasia during the last few years. Although of slow growth and rarely enticing metastases, its extension and location offer great therapeutic difficulties when it involves the periocular region.The surgical treatment is the one currently used for the periocular region, however, new therapeutic methods have been proposed. The reparative surgical techniques might jeopardize so much the eyelid function (ocular protection) as well as the region aesthetic balance. Recently a new approach involving a clinical treatment using topics immune response modifier has been tried. Imiquimod cream 5% is the main representative of this new class of medications, it has been widely studied in the recent past and it has shown great effectiveness in the treatment of the basal cell carcinoma.he purpose of this current work is accomplishing a systematic analysis of the relevant literature that supports the use of imiquimod cream 5% in the periocular basal cell carcinoma treatment.

Keywords : Carcinoma, basal cell [drug therapy]; Antineoplastic agents [therapeutic use]; Immunologic factors; Eyelid neoplasms [pathology]; Review literature.

        · abstract in Portuguese     · text in Portuguese     · Portuguese ( pdf epdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License